A heart surgeon says the number of artery-clogging particles, not just the cholesterol inside them, should guide how we prevent heart attacks—and that shifts how we think about statins.
Story Snapshot
- Apolipoprotein B (apoB) counts risky particles and can refine risk beyond LDL cholesterol.
- Guidelines use apoB as a risk-enhancing factor, not a full replacement for LDL cholesterol.
- Statins remain effective tools with strong outcome data when risk stays high.
- Jeremy London urges lifestyle first, then meds if apoB stays high after 3–6 months.
ApoB reframes the core risk question
Jeremy London, a board-certified cardiovascular surgeon, argues that apoB measures what matters most: the number of atherogenic particles that can enter artery walls and spark plaque. That frame moves the focus from “how much cholesterol” to “how many delivery trucks.” When low-density lipoprotein cholesterol and apoB do not match, apoB better mirrors risk in many people, especially with high triglycerides or insulin resistance, according to major reviews and guidance.
London’s video explains how to lower apoB through diet quality, fiber, weight loss, and exercise, and then through medication when needed. He supports statins as proven therapies that cut events. He also reviews ezetimibe, proprotein convertase subtilisin/kexin type 9 inhibitors, and bempedoic acid as add-ons or options when statins alone are not enough or not tolerated. He proposes a three-to-six-month push on lifestyle before adding medicine, provided absolute risk is not already high.
What guidelines actually say—and where apoB fits
The 2018 American Heart Association and American College of Cardiology guideline keeps low-density lipoprotein cholesterol at the center, especially for people with very high low-density lipoprotein cholesterol, diabetes, or clinical atherosclerotic disease. It lists apoB at or above 130 milligrams per deciliter as a risk-enhancing factor, which can tilt the decision toward a statin in borderline or intermediate risk adults. It does not call for universal apoB testing or replace low-density lipoprotein cholesterol across the board.
That stance leaves room for smart use of apoB without discarding simple markers. The logic is plain: when the standard picture is fuzzy, bring in a sharper lens. ApoB can add that lens. For patients with mixed lipids, high triglycerides, or signs of insulin resistance, apoB can expose risk that a standard panel misses. That added clarity can help patients and clinicians choose whether to start or intensify therapy.
Statins remain the backbone when risk is real
Outcome trials show that statins lower heart attack and stroke risk in the right patients. The case for using them rests on event cuts, not just nicer numbers on a lab printout. London’s take aligns with that: lifestyle is the base, and medicines are tools to hit risk goals when lifestyle alone does not get apoB or low-density lipoprotein cholesterol to safer ranges. That approach follows the guideline spirit of shared decisions anchored to absolute risk and proven benefit.
Some viewers may hear “apoB first” and think it means “statins never.” That is not the message. The message is sequence and precision: improve diet quality, move more, lose visceral fat, and then reassess. If risk remains high, use statins and, if needed, add non-statin drugs to reach targets that link to fewer events. That blend respects personal choice while honoring evidence that medicines save lives when baseline risk is above key thresholds.
How to put this into practice without the hype
Ask for a clear risk picture that includes standard lipids, blood pressure, age, smoking, diabetes, and family history. When results clash—like normal low-density lipoprotein cholesterol with high triglycerides or signs of insulin resistance—ask about apoB to clarify risk. If apoB is high, push hard on two meals of lean protein and plants per day, 25 to 30 grams of fiber, and daily activity. Recheck in three months. If numbers and risk stay high, start a statin and aim for a sustained, trackable drop.
Why this matters now
Public debate often swings between “statins for all” and “statins are bad.” That noise hurts patients. The better path uses common sense: match the tool to the job, and measure what predicts harm. ApoB helps size up particle burden. Statins cut events when used for the right people at the right time. Lifestyle lifts every part of this plan. Keep the focus on risk, results, and responsible follow-up—not on online hot takes or false choices.
Sources:
acc.org, ahajournals.org, linkedin.com
